A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue 3, 1996, Pages 235-246

  Japour, Anthony J ^a   Lertora, Juan J ^b   Meehan, Patricia M ^c,d   Erice, Alejo ^e   Connor, James D ^f   Griffith, Brigitte P ^g,h   Clax, Pamela A ⁱ   Holden Wiltse, Jeanne ^c,d   Hussey, S ^a   Walesky, Mary ^g,h   Cooney, Elizabeth ^g,h   Pollard, Richard ^j   Timpone, Joseph ⁱ   McLaren, Colin ^k   Johanneson, Nils ^l   Wood, Kenneth ^k   Booth, David K ^m   Bassiakos, Yannis ^c,d   Crumpacker, Clyde S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^k BRISTOL MYERS SQUIBB   (United States)

^l Valeant Pharmaceuticals International   (United States)

^m RTI INTERNATIONAL   (United States)

more..

Author keywords

Didanosine; HIV 1; Phase I study; Ribavirin

Indexed keywords

DIDANOSINE; RIBAVIRIN;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 1542533733     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199611010-00005     Document Type: Article

References (35)

1. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III by 2′,3′-dideoxynucleotides. Proc Natl Acad Sci USA 1986;83:1911-5.
2. Perno C-F, Yarchoan R, Cooney D, et al. Inhibition of human immunodeficiency virus replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med 1988;168:1111-25.
3. Ahluwalia G, Cooney D, Mitsuya H, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 1987;36:3797-800.
4. Jackson JB, Coombs RW, Sannerud K, Rhame FS, Balfour HH. Rapid and sensitive viral culture method for HIV type-1. J Clin Microbiol 1988;26:1416-8.
5. Johnson M, Fridland A. Phosphorylation of 2′,3′-dideoxyinosine by cytosclic 5′-nucleotidase of human lymphoid cells. Mol Pharmacol 1989;1989:291-5.
6. Gilbert B, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 1986;30:201-5.
7. Roberts R, Jurica K, Meyer W, Praxton H, Makuch R. A phase 1 study of ribavirin in human immunodeficiency virus-infected patients. J Infect Dis 1990;162:638-42.
8. Roberts RB, Dickinson GM, Heseltine PN, et al. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy: the Ribavirin-LAS Collaborative Group [see comments]. J Acquir Immune Defic Syndr 1990; 3:884-92 [Erratum, J Acquir Immune Defic Syndr 1991;4: 450].
9. Crumpacker C, Pearlstein G, Van der Horst C, Valentine F, Spector S, Mills J. A phase one increasing dose trial of ribavirin in patients with AIDS and ARC (ACTG 034) [Abstract]. In: Sixth International Conference on AIDS, San Francisco, CA, 1990. Int AIDS Conf 1990, June 20-23, 6(3):203 (Abst SB 468).
10. Hartman N, Ahluwalia G, Cooney D, et al. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-HIV nucleosides 2′,3′-dideoxyadenosine and 2′,3′-didoxyinosine. Mol Pharmacol 1991;40:118-24.
11. Streeter D, Witkowski J, Khare G. Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad spectrum antiviral agent. Proc Natl Acad Sci USA 1973;70:1174-8.
12. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J. Ribavirin antagonizes inhibitory effect of pyrimidine 2′,3′-dideoxynucleosides but enhanced inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in-vitro. Antimicrob Agents Chemother 1987;31:1613-7.
13. Ahluwalia G, Cooney D, Bondoc L, et al. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2′,3′-dideoxyguanosine. Biochem Biophys Res Commun 1990;171:1297-303.
14. Balzarini J, Naesens L, De Clercq E. Potentiating effect of ribavirin on the in-vitro and in-vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. J Acquir Immune Defic Syndr 1990;3:1140-7.
15. Johns DG, Ahluwalia GS, Counet DA, Mitsuya H, Driscoll JS. Enhanced stimulation by ribavirin of the 5′ phosphorylation and anti-human immunodeficiency virus activity of purine 2′-β-fluoro-2′,3′-dideoxynucleosides. Mol Pharmacol 1993;44:517-23.
16. Japour A, Chatis P, Eigenrauch H, Kim L, Crumpacker C. DDI potentiation by ribavirin. In: Seventh International Conference on AIDS, Florence, Italy, 1991; vol 2. Int AIDS Conf 1991, June 16-21, 7(2):97 (Abst. WA1021).
17. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327:581-7.
18. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection: the Terry Beirn Community Programs for Clinical Research on AIDS [see comments]. N Engl J Med 1994;330: 657-62.
19. Dolin R, Amato DA, Fischl MA, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine: AIDS Clinical Trials Group. Arch Intern Med 1995;155:961-74.
20. Crumpacker C, Heagy W, Bubley G, et al. Ribavirin treatment of AIDS and ARC: a phase I study shows transient clinical improvement associated with suppression of HIV and enhanced lymphocyte proliferation. Ann Intern Med 1987;107:664-74.
21. Lertora J, Rege A, Lacour J, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients with human immunodeficiency virus. Clin Pharmacol Ther 1991;50:442-9.
22. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-Dideoxyinosine (ddI) in patients with the AIDS or ARC. N Engl J Med 1990;322:1333-40.
23. Drusano GL, Yuen GJ, Lambert JS, Seidlin M, Dolin R, Valentine FT. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection: a phase I trial. Ann Intern Med 1992;116:562-6.
24. Beltangady M, Knupp CA, Gustafson N, et al. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex. Clin Infect Dis 1993;16(suppl 1):S26-31.
25. Dimitrov D, Melnick J, Hollinger F. Microculture assay for isolation of human immunodeficiency virus type 1 for titration of infected peripheral blood mononuclear cells. J Clin Microbiol 1990;28:734-7.
26. Japour A, Fiscus S, Arduino J, Mayers D, Reichelderfer P, Kuritzkes D. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994; 32:2291-41.
27. Myers L, McQuay L, Hollinger F. Dilution assay statistics. J Clin Microbiol 1994;32:732-9.
28. Van Gemen B, Kievets T, Schukkink R, et al. Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. J Virol Methods 1993;43:177-88.
29. Van Gemen B, Van Beuningen R, Nabbe M, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification using electrochemiluminescent (ECL) labelled probes. J Virol Methods 1994;49:157-68.
30. Boom R, Sol C, Salimans M, Jansen C, Wertheim-Van Dillen P, Van Der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
31. St. Clair M, Martin J, Tudor-Williams G, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
32. Kalin J, Hill D. Determination of 2′,3′-dideoxyadenosine, 2′,3′-dideoxyinosine, and 2′,3′-dideoxycytidine in biologic samples. J Chromatogr 1988;431:184-91.
33. Austin R, Trefts P, Hintz M, Connor J, Kagnoff M. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob Agents Chemother 1983;24:696-701.
34. Weerahandi S. Exact statistical methods for data analysis. New York: Springer-Verlag, 1995.
35. Welles S, Jackson J, Yen-Lieberman B, et al. Prognostic value of plasma HIV-1 RNA levels in patients with advanced HIV-1 disease and with little or no zidovudine therapy. J Infect Dis 1995 (in press).